Coca-Cola FEMSA, S.A.B. de C.V. (KOF)
NYSE: KOF · Real-Time Price · USD
83.43
+0.39 (0.47%)
Aug 1, 2025, 4:00 PM - Market closed
Aerovate Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Aerovate Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $105.5, which forecasts a 26.45% increase in the stock price over the next year. The lowest target is $100 and the highest is $113.
Price Target: $105.50 (+26.45%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aerovate Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $105 → $100 | Buy | Maintains | $105 → $100 | +19.86% | Jul 31, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $111 → $107 | Hold | Maintains | $111 → $107 | +28.25% | Jul 16, 2025 |
| UBS | UBS | Strong Buy Maintains $109 → $113 | Strong Buy | Maintains | $109 → $113 | +35.44% | Jul 8, 2025 |
| UBS | UBS | Strong Buy Maintains $106 → $109 | Strong Buy | Maintains | $106 → $109 | +30.65% | May 5, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $107 → $110 | Buy | Maintains | $107 → $110 | +31.85% | Apr 11, 2025 |
Financial Forecast
Revenue This Year
307.27B
from 279.79B
Increased by 9.82%
Revenue Next Year
333.92B
from 307.27B
Increased by 8.67%
EPS This Year
128.67
from 112.96
Increased by 13.91%
EPS Next Year
144.18
from 128.67
Increased by 12.05%
Financial currency is MXN. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 329.3B | 362.3B | 391.3B | ||
| Avg | 307.3B | 333.9B | 355.3B | ||
| Low | 284.2B | 301.5B | 319.8B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 17.7% | 17.9% | 17.2% | ||
| Avg | 9.8% | 8.7% | 6.4% | ||
| Low | 1.6% | -1.9% | -4.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 145.11 | 170.00 | 170.63 |
| Avg | 128.67 | 144.18 | 158.23 |
| Low | 119.07 | 130.93 | 147.88 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 28.5% | 32.1% | 18.3% |
| Avg | 13.9% | 12.1% | 9.7% |
| Low | 5.4% | 1.8% | 2.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.